News

Video

Advancements in Prostate Cancer Imaging: The Evolution of PET Scans

Author(s):

David Albala, MD

Explore the transformative journey of prostate cancer imaging techniques, from conventional methods to cutting-edge PET scans like F-18 PSMA, and how FDA approvals have shaped their adoption.

Current Time 0:00
Duration 4:44
Loaded: 3.46%
Stream Type LIVE
Remaining Time 4:44
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
    Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
    Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
    Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
    Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
    Betty Wang, MD, discusses studies from the 2025 EAU meeting
    Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
    Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
    Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
    Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
    Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
    Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
    Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
    Dr Louise Kostos answers a question during a Zoom video interview
    Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
    Dr Louise Kostos answers a question during a Zoom video interview
    An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
    Related Content
    Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
    May 2nd 2025

    Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

    Hannah Clarke
    The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    ARANOTE substudy highlights benefits of darolutamide in Black men
    April 28th 2025

    ARANOTE substudy highlights benefits of darolutamide in Black men

    Benjamin P. Saylor
    The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health
    April 26th 2025

    TikTok, social media does more harm than good for prostate cancer education

    Patrick Campbell
    Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.
    Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
    April 25th 2025

    FDA clears AI-powered application for measuring prostate volume

    Benjamin P. Saylor
    Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.
    © 2025 MJH Life Sciences

    All rights reserved.